The European Hematology Association (EHA) and the EHA Scientific Working Group on Acute Lymphoblastic Leukemia are organizing their second EHA-SWG Scientific Meeting on Acute Lymphoblastic Leukemia on 12-14 April, 2018 in Barcelona, Spain.
Considerable progress has been made in the management of ALL in the past decade and a number of exciting new compounds are under development. Furthermore, new biologic subgroups and their respective diagnostic strategies have been described. The activities of European ALL study groups greatly contributed to this success. These rapid developments are a challenge for patient treatment and clinical science.The EHA-SWG Scientific Meeting on ALL aims to bring clinicians and young scientists together with leading international experts to facilitate exchange and expand the networks of national study groups to a European level.
HARMONY Partners involved are
Direct link to the EHA-SWG meeting page.
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
